The Effect of Raltegravir on the Glucuronidation of Lamotrigine

Journal of Clinical Pharmacology

Volumn 49, Issue 10, 2009, Pages 1220-1227

  Van Luin, Matthijs ^a,b   Colbers, Angela ^a   Verwey Van Wissen, Corrien P W G M ^a   Van Ewijk Beneken Kolmer, Eleonora W J ^a   Van Der Kolk, Mike ^a   Hoitsma, Arjen ^a   Gomes Da Silva, Hugo ^c   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Drug drug interactions; Glucuronidation; Lamotrigine; Raltegravir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG METABOLITE; LAMOTRIGINE; LAMOTRIGINE 2N GLUCURONIDE; RALTEGRAVIR; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE;

ADULT; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PYRROLIDINONES; TRIAZINES;

EID: 70349496064     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009345689     Document Type: Article

References (25)

1. 48-week data on raltegravir in naive patients. AIDS Patient Care STDS. 2007 ; 21: 703.
2. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008 ; 359: 339-354.
3. Iwamoto M., Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008 ; 47: 137-140.
4. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009 ; 53: 2852-2856.
5. Hanley WD, Wenning LA, Moreau A., et al. Effect of tipranavir + ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009 ; 53: 2752-2755.
6. Anderson MS, Kakuda TN, Hanley W., et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008 ; 52: 4228-4232.
7. Iwamoto M., Kassahun K., Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 2008 ; 48: 209-214.
8. Food and Drug Administration. Isentress [prescribing information]. http://www.fda.gov/cder/foi/label/2009/022145s001lbl.pdf. Accessed May 5, 2009.
9. Glaxo Smith Kline. Summary of product characteristics: Lamictal. In: SmPC Lamictal, approved by The Medicines Evaluation Board, the Netherlands. Zeist, The Netherlands: Glaxo Smith Kline ; 2005.
10. Mullin P., Green G., Bakshi R. Special populations: the management of seizures in HIV-positive patients. Curr Neurol Neurosci Rep. 2004 ; 4: 308-314.
11. Satishchandra P., Sinha S. Seizures in HIV-seropositive individuals: NIMHANS experience and review. Epilepsia. 2008 ; 49 (suppl 6). 33-41.
12. Simpson DM, McArthur JC, Olney R., et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003 ; 60: 1508-1514.
13. Van der Lee MJ, Dawood L., ter Hofstede HJ, et al. Lopinavir/ ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006 ; 80: 159-168.
14. Burger DM, Huisman A., Van EN, et al. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther. 2008 ; 84: 698-703.
15. European Medicines Agency (EMEA). Isentress: Summary of Product Characteristics. http://www.emea.europa.eu/humandocs/ PDFs/EPAR/isentress/H-860- PI-en.pdf. Accessed May 5, 2009. 16. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008;83:293-299.
16. US Department of Health and Human Services, Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. www.fda.gov/cder/guidance/index.htm. Accessed December 18, 2008.
17. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008 ; 52: 3253-3258.
18. Kiang TK, Ensom MH, Chang TK UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 ; 106: 97-132.
19. Yuen AW, Land G., Weatherley BC, Peck AW Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992 ; 33: 511-513.
20. Lee BL, Tauber MG, Sadler B., Goldstein D., Chambers HF Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther. 1996 ; 59: 14-21.
21. Argikar UA, Remmel RP Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 ; 39: 355-363.
22. Markowitz M., Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as mono-therapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006 ; 43: 509-515.
23. Bruguerolle B. Chronopharmacokinetics: current status. Clin Pharmacokinet. 1998 ; 35: 83-94.
24. Labrecque G., Belanger PM Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol Ther. 1991 ; 52: 95-107.
25. Wenning L., Anderson M., Petry A., et al. Raltegravir (RAL) dose proportionality and effect of food. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy ; September 17-20, 2007 ; Chicago, Illinois. Abstract no. H-1046.